Pierre Fabre Supercritical Fluids to exhibit taste masking and deep cleaning breakthroughs at CRS Expo

Gaillac, France: – Pierre Fabre Medicament’s highly Innovative Supercritical Fluids Division will exhibit its breakthrough technologies, including taste-masking and deep cleaning, at Controlled Release Society (CRS) annual meeting in Edinburgh on July 27th and 28th 2015.

The Supercritical Fluids team at Booth 501 at the Edinburgh International Conference Centre will have news of its latest advances made in application of supercritical carbon dioxide to life sciences.

Revolutionizing drug delivery

The division will also exhibit applications of its patented Formulcoat®, Formulplex® and Formuldisp® technologies to pharmaceutical pre-formulation applications including taste-masking of bitter ingredients, enhancement of solubility and bioavailability of API.

“At CRS, we will be showing our visitors how our unique expertise in supercritical carbon dioxide makes a whole suite of applications possible,” explained Hubert Lochard, R&D Project Manager for Pierre Fabre Group, who will be leading the Supercritical Fluids Division team in Edinburgh.

“Our display will explain how we can apply our contract manufacturing technologies to drug delivery applications, particularly to taste-masking of bitter active ingredients. Formulcoat can coat substances in ways that allow laboratories to develop new oral delivery forms for API until now too bitter to be administrated in an orodispersible form for instance,” Mr. Lochard said.

“Supercritical Fluids technologies can optimize new API formulations for Life Cycle Management,” he added.

Deep cleaning breakthrough

The newest service of the supercritical fluids unit is the deep cleaning of implants and medical components, solving problems with extractable and leachable substances.

The Supercritical Fluids stand will also show how supercritical CO2 can penetrate to the heart of porous solids, generating consistent cleaning in depth. This technology is particularly suitable for the removal of extractables or leachables present in elastomers or cross-linked polymers, the scouring of textile, the degreasing of porous materials, with the advantage to have no residual solvent.

About Pierre Fabre Medicament

Pierre Fabre Médicament is one of France’s largest independent pharmaceutical laboratories, focusing on ethical drugs, health products and dermocosmetic products.

Headquartered at Castres in the French Midi-Pyrenees Departement, Pierre Fabre has a presence in more than 130 countries worldwide and has a combined workforce of more than 10,000 people of whom more than 3.000 work outside France.

Founded in 1962, company’s business activity is focused on research, development, manufacturing and marketing of cosmetics, prescription medicines and family health products.

Pierre Fabre Medicament is especially known for its vinca alkaloid anticancer drug Navelbine (vinorelbine).

PFMP’s six manufacturing sites are able to develop and manufacture active ingredients, dry forms (tablets and capsules) liquid and semi-solid forms, lozenges and injectables. PFMP plants are approved to FDA, PMDA, ANVISA and EMEA standards.

Pierre Fabre’s Supercritical Fluids division has developed specialized expertise in supercritical fluids technology for pharmaceutical applications, in particular in Drug Delivery Systems (DDS).

The highlight of PFM SuperCritical Fluids is to be a GMP unit.

About CRS 2015

The Controlled Release Society (CRS) is a not-for-profit organization devoted to the science and technology of controlled release.

The society recognizes that since its origins in the development of the first commercially successful oral sustained-release products in the late 1940s, controlled release has grown and broadened in scope to encompass scientific and technical efforts to regulate the spatial and temporal effects of agents in diverse areas including human and animal health as well as non-pharmaceutical areas such as agriculture, cosmetics, consumer products, and the environment.

The CRS 42nd Annual Meeting and Exposition is a four-day event opening July 26 at the Edinburgh International Conference Centre in Scotland’s capital and expected to attract more than 1,100 visitors from more than 40 countries. The 2015 meeting will feature more than 200 scientific presentations and 950 posters, more than any previous conference.

More information at: www.controlledreleasesociety.org/meetings/annual/Pages/default.aspx